Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

MLA

Takeru Shiroiwa, et al. “Cost-Effectiveness Analysis of the Introduction of S-1 Therapy for First-Line Metastatic Breast Cancer Treatment in Japan: Results from the Randomized Phase III SELECT BC Trial.” BMC Cancer, vol. 17, no. 1, Nov. 2017, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-017-3774-7.

APA

Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Mitsuko Mouri, Yasuhiro Hagiwara, Takuya Kawahara, Shozo Ohsumi, Yasuo Hozumi, Yoshiaki Sagara, Yasuo Ohashi, & Hirofumi Mukai. (2017). Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC Cancer, 17(1), 1–10. https://doi.org/10.1186/s12885-017-3774-7

Chicago

Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Mitsuko Mouri, Yasuhiro Hagiwara, Takuya Kawahara, Shozo Ohsumi, et al. 2017. “Cost-Effectiveness Analysis of the Introduction of S-1 Therapy for First-Line Metastatic Breast Cancer Treatment in Japan: Results from the Randomized Phase III SELECT BC Trial.” BMC Cancer 17 (1): 1–10. doi:10.1186/s12885-017-3774-7.